Ost-müük 4D Molecular Therapeutics, Inc. - FDMT CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | - | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.030779% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | -0.013666% | ||||||||
| Ööpäeva tasu aeg | 22:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | N/A |
| Avatud* | N/A |
| Aastane muutus* | N/A |
| Päeva ulatus* | N/A |
| 52 nädala ulatus | 5.32-26.49 |
| Keskmine maht (10 päeva) | 251.07K |
| Keskmine maht (3 kuud) | 10.31M |
| Turukapitalisatsioon | 746.64M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 32.39M |
| Tulu | 1.97M |
| EPS | -3.30 |
| Dividendid (% kasumist) | N/A |
| Beeta | -100.00K |
| Järgmine tuluaruande kuupäev | Mar 27, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|
4D Molecular Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Kogutulu | 5.79 | 14.13 | 6.986 | 13.612 | 18.038 |
| Tulu | 5.79 | 14.13 | 6.986 | 13.612 | 18.038 |
| Kogu tegevuskulu | 17.062 | 24.529 | 57.75 | 70.276 | 89.371 |
| Müük/Üldine/admin kulud, kokku | 3.489 | 6.167 | 13.895 | 17.238 | 28.011 |
| Uuringud ja arendus | 13.573 | 18.362 | 38.718 | 53.038 | 61.36 |
| Tulud majandustegevusest | -11.272 | -10.399 | -50.764 | -56.664 | -71.333 |
| Intressitulud (kulu), muud tulud, neto | 0.089 | 0.85 | 1.504 | 0.152 | 0.137 |
| Muud, neto | -0.04 | -0.002 | -0.046 | -0.181 | -0.121 |
| Netotulu enne makse | -11.223 | -9.551 | -49.306 | -56.693 | -71.317 |
| Netotulu pärast makse | -11.223 | -9.551 | -49.306 | -56.693 | -71.317 |
| Netotulu enne erikulusid | -11.223 | -9.551 | -49.306 | -56.693 | -71.317 |
| Netotulu | -11.223 | -9.551 | -49.306 | -56.693 | -71.317 |
| Arvestatav tulu, v a erikulud | -11.223 | -9.551 | -49.306 | -56.693 | -71.317 |
| Arvestatav tulu, koos erikuludega | -11.223 | -9.551 | -49.306 | -56.693 | -71.317 |
| Jaotamisele kuuluv netotulu | -11.223 | -9.551 | -49.306 | -56.693 | -71.317 |
| Keskmine jaotamisele kuuluv aktsia kohta | 5.25774 | 5.25774 | 5.25774 | 26.682 | 27.7304 |
| Jaotatav EPS, v a erakorralised kulud | -2.13457 | -1.81656 | -9.37779 | -2.12477 | -2.5718 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Jaotamisele kuuluv normaal-EPS | -2.13457 | -1.81656 | -8.40075 | -2.12477 | -2.5718 |
| Ootamatud kulutused (tulu) | 0 | 5.137 | 0 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 2 | 14.58 | 1.366 | 0.092 | 1.219 |
| Tulu | 2 | 14.58 | 1.366 | 0.092 | 1.219 |
| Kogu tegevuskulu | 18.312 | 22.176 | 24.027 | 24.856 | 27.611 |
| Müük/Üldine/admin kulud, kokku | 5.543 | 6.953 | 8.187 | 7.328 | 8.23 |
| Uuringud ja arendus | 12.769 | 15.223 | 15.84 | 17.528 | 19.381 |
| Tulud majandustegevusest | -16.312 | -7.596 | -22.661 | -24.764 | -26.392 |
| Intressitulud (kulu), muud tulud, neto | 0.007 | 0.007 | 0.435 | -0.312 | 0.1 |
| Muud, neto | -0.101 | 0 | -0.013 | -0.007 | -0.046 |
| Netotulu enne makse | -16.406 | -7.589 | -22.239 | -25.083 | -26.338 |
| Netotulu pärast makse | -16.406 | -7.589 | -22.239 | -25.083 | -26.338 |
| Netotulu enne erikulusid | -16.406 | -7.589 | -22.239 | -25.083 | -26.338 |
| Netotulu | -16.406 | -7.589 | -22.239 | -25.083 | -26.338 |
| Arvestatav tulu, v a erikulud | -16.406 | -7.589 | -22.239 | -25.083 | -26.338 |
| Arvestatav tulu, koos erikuludega | -16.406 | -7.589 | -22.239 | -25.083 | -26.338 |
| Jaotamisele kuuluv netotulu | -16.406 | -7.589 | -22.239 | -25.083 | -26.338 |
| Keskmine jaotamisele kuuluv aktsia kohta | 26.6902 | 26.7391 | 27.0224 | 30.4659 | 32.2324 |
| Jaotatav EPS, v a erakorralised kulud | -0.61468 | -0.28382 | -0.82298 | -0.82331 | -0.81713 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.61468 | -0.28382 | -0.82298 | -0.82331 | -0.81713 |
- Aastas
- Kvartalis
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 24.499 | 94.068 | 52.508 | 282.656 | 256.28 |
| Raha ja lühiajalised investeeringud | 23.85 | 91.761 | 49.652 | 276.726 | 247.777 |
| Raha ja ekvivalendid | 23.85 | 91.761 | 49.652 | 276.726 | 153.001 |
| Laekumata arved, neto | 0.321 | 1.124 | 0.978 | 1.486 | 0.047 |
| Accounts Receivable - Trade, Net | 0.321 | 1.124 | 0.978 | 1.486 | 0.047 |
| Prepaid Expenses | 0.328 | 0.783 | 0.678 | 2.844 | 7.456 |
| Total Assets | 27.32 | 96.969 | 58.234 | 288.331 | 353.487 |
| Property/Plant/Equipment, Total - Net | 2.716 | 2.472 | 5.049 | 5.073 | 28.953 |
| Property/Plant/Equipment, Total - Gross | 3.68 | 4.124 | 7.674 | 8.917 | 34.278 |
| Accumulated Depreciation, Total | -0.964 | -1.652 | -2.625 | -3.844 | -5.325 |
| Other Long Term Assets, Total | 0.105 | 0.429 | 0.677 | 0.602 | 0.602 |
| Total Current Liabilities | 5.908 | 8.054 | 12.955 | 16.744 | 16.338 |
| Accounts Payable | 0.46 | 0.954 | 1.744 | 1.787 | 4.764 |
| Accrued Expenses | 0.987 | 1.644 | 3.108 | 4.797 | 7.402 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 4.461 | 5.456 | 8.103 | 10.16 | 4.172 |
| Total Liabilities | 28.402 | 21.576 | 28.224 | 31.944 | 34.38 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 22.494 | 13.522 | 15.269 | 15.2 | 18.042 |
| Total Equity | -1.082 | 75.393 | 30.01 | 256.387 | 319.107 |
| Redeemable Preferred Stock | 18.508 | 102.98 | 102.98 | 0 | 0 |
| Common Stock | 0.001 | 0.001 | 0.001 | 0.003 | 0.003 |
| Additional Paid-In Capital | 0.884 | 2.438 | 6.054 | 392.063 | 526.523 |
| Retained Earnings (Accumulated Deficit) | -20.475 | -30.026 | -79.025 | -135.679 | -206.996 |
| Total Liabilities & Shareholders’ Equity | 27.32 | 96.969 | 58.234 | 288.331 | 353.487 |
| Total Common Shares Outstanding | 5.25774 | 5.25774 | 5.25774 | 26.682 | 32.2245 |
| Other Current Assets, Total | 0.4 | 1.2 | 1.6 | 1 | |
| Lühiajalised investeeringud | 94.776 | ||||
| Long Term Investments | 67.652 | ||||
| Other Equity, Total | -0.423 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 264.501 | 248.752 | 165.733 | 256.28 | 243.047 |
| Raha ja lühiajalised investeeringud | 259.865 | 243.743 | 161.675 | 247.777 | 236.153 |
| Raha ja ekvivalendid | 259.865 | 243.743 | 90.989 | 153.001 | 75.97 |
| Laekumata arved, neto | 0.965 | 1.218 | 0.791 | 0.047 | 0 |
| Accounts Receivable - Trade, Net | 0.965 | 1.218 | 0.791 | 0.047 | 0 |
| Prepaid Expenses | 2.071 | 2.291 | 1.567 | 7.456 | 6.294 |
| Other Current Assets, Total | 1.6 | 1.5 | 1.7 | 1 | 0.6 |
| Total Assets | 270.114 | 254.934 | 240.618 | 353.487 | 324.926 |
| Property/Plant/Equipment, Total - Net | 5.011 | 5.58 | 8.789 | 28.953 | 32.642 |
| Property/Plant/Equipment, Total - Gross | 9.229 | 10.168 | 13.759 | 34.278 | 38.374 |
| Accumulated Depreciation, Total | -4.218 | -4.588 | -4.97 | -5.325 | -5.732 |
| Other Long Term Assets, Total | 0.602 | 0.602 | 0.602 | 0.602 | 0.875 |
| Total Current Liabilities | 13.916 | 9.87 | 11.373 | 16.338 | 12.091 |
| Accounts Payable | 1.284 | 1.962 | 3.713 | 4.764 | 2.681 |
| Accrued Expenses | 3.1 | 4.146 | 4.739 | 7.402 | 6.081 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 9.532 | 3.762 | 2.921 | 4.172 | 3.329 |
| Total Liabilities | 27.683 | 14.288 | 16.484 | 34.38 | 28.87 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 13.767 | 4.418 | 5.111 | 18.042 | 16.779 |
| Total Equity | 242.431 | 240.646 | 224.134 | 319.107 | 296.056 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
| Additional Paid-In Capital | 394.513 | 400.317 | 406.239 | 526.523 | 530.808 |
| Retained Earnings (Accumulated Deficit) | -152.085 | -159.674 | -181.913 | -206.996 | -233.334 |
| Total Liabilities & Shareholders’ Equity | 270.114 | 254.934 | 240.618 | 353.487 | 324.926 |
| Total Common Shares Outstanding | 26.6944 | 26.8919 | 27.1656 | 32.2245 | 32.2641 |
| Lühiajalised investeeringud | 70.686 | 94.776 | 160.183 | ||
| Long Term Investments | 65.494 | 67.652 | 48.362 | ||
| Other Equity, Total | -0.195 | -0.423 | -1.421 |
- Aastas
- Kvartalis
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -11.223 | -9.551 | -49.306 | -56.693 | -71.317 |
| Raha majandustegevusest | 8.237 | -16.252 | -36.711 | -50.909 | -69.134 |
| Raha majandustegevusest | 0.626 | 0.697 | 1.004 | 1.443 | 1.523 |
| Mittelikviidsed varad | 0.295 | 1.379 | 11.332 | 5.052 | 16.194 |
| Muutused tööjõus | 18.539 | -8.777 | 0.259 | -0.711 | -15.534 |
| Tulu investeeringutelt | 7.675 | -0.414 | -3.203 | -1 | -172.68 |
| Kapitalikulutused | -0.573 | -0.414 | -3.203 | -1 | -9.11 |
| Muud rahavood investeeringutelt, kokku | 8.248 | 0 | -163.57 | ||
| Rahavood investeeringutelt | 0.016 | 84.577 | -2.195 | 278.983 | 118.089 |
| Rahavoogudesse investeerimine | 0 | 0 | -2.27 | ||
| Aktsiate emiteerimine (tagasiost), neto | 0.016 | 84.577 | 0.075 | 278.983 | 118.089 |
| Rahaline kogumuutus | 15.928 | 67.911 | -42.109 | 227.074 | -123.725 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.406 | -23.995 | -46.234 | -71.317 | -26.338 |
| Cash From Operating Activities | -15.372 | -31.577 | -47.298 | -69.134 | -23.55 |
| Cash From Operating Activities | 0.381 | 0.751 | 1.133 | 1.523 | 0.406 |
| Non-Cash Items | 2.445 | 6.276 | 10.228 | 16.194 | 4.92 |
| Changes in Working Capital | -1.792 | -14.609 | -12.425 | -15.534 | -2.538 |
| Cash From Investing Activities | -0.642 | -1.379 | -140.389 | -172.68 | -54.11 |
| Capital Expenditures | -0.642 | -1.379 | -4.014 | -9.11 | -6.413 |
| Cash From Financing Activities | -0.847 | -0.027 | 1.95 | 118.089 | 0.629 |
| Financing Cash Flow Items | -0.946 | -0.946 | -0.946 | -0.246 | |
| Issuance (Retirement) of Stock, Net | 0.099 | 0.919 | 2.896 | 118.089 | 0.875 |
| Net Change in Cash | -16.861 | -32.983 | -185.737 | -123.725 | -77.031 |
| Other Investing Cash Flow Items, Total | -136.375 | -163.57 | -47.697 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| BVF Partners L.P. | Hedge Fund | 12.3715 | 4007413 | 0 | 2022-09-30 | LOW |
| Viking Global Investors LP | Investment Advisor/Hedge Fund | 12.1569 | 3937914 | 0 | 2022-09-30 | MED |
| Deep Track Capital LP | Hedge Fund | 9.8685 | 3196642 | 56642 | 2022-09-30 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.0639 | 1964232 | 17894 | 2022-09-30 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 5.9583 | 1930047 | 1886130 | 2022-09-30 | MED |
| Kirn (David M.D.) | Individual Investor | 5.8458 | 1893599 | -19524 | 2023-01-20 | LOW |
| ArrowMark Colorado Holdings, LLC | Investment Advisor/Hedge Fund | 4.7232 | 1529958 | 105644 | 2022-09-30 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 4.0742 | 1319731 | -15317 | 2022-09-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.0604 | 1315271 | -1787 | 2022-09-30 | LOW |
| Schaffer (David) | Individual Investor | 2.7822 | 901215 | -36285 | 2021-12-31 | |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.0905 | 677176 | 44651 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6329 | 528936 | 36111 | 2022-09-30 | LOW |
| Octagon Capital Advisors LP | Hedge Fund | 1.5436 | 499996 | -132749 | 2022-09-30 | MED |
| Eagle Health Investments LP | Hedge Fund | 1.1373 | 368411 | 106988 | 2022-09-30 | MED |
| Opaleye Management Inc. | Hedge Fund | 1.0827 | 350700 | 25700 | 2022-09-30 | LOW |
| Janke (Theresa) | Individual Investor | 1.0806 | 350030 | 350030 | 2022-03-28 | |
| Pfizer Inc | Corporation | 1.0547 | 341658 | -1325000 | 2021-12-31 | MED |
| Point72 Asset Management, L.P. | Hedge Fund | 0.9231 | 299000 | 299000 | 2022-09-30 | HIGH |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.9076 | 294000 | 294000 | 2022-12-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 0.8897 | 288204 | -412248 | 2022-09-30 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group +485000+
Kauplejad
65000+
Igakuiste aktiivsete klientide arv
$48000000+
Igakuine investeerimise maht
$28000000+
Proovige nüüd Igakuiselt välja võetud
Kauplemiskalkulaator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Kauplemise vahendustasu
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finantsvõimendus
20:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
4D Molecular Therapeutics, Inc. Company profile
Ettevõttest 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. on kliinilise staadiumi geeniteraapia ettevõte. Ettevõte keskendub oma adeno-assotsieerunud viirustel (AAV) põhinevate sihtotstarbeliste ravimeetodite väljatöötamisele. Ettevõte kasutab oma Therapeutic Vector Evolution platvormi, et kohandada oma AAV-vektoreid nii, et need oleksid suunatud konkreetsetele haigusega seotud koetüüpidele. Ettevõte keskendub kolmele ravivaldkonnale: oftalmoloogia (intravitreaalne vektor), kardioloogia (intravenoosne vektor) ja pulmonoloogia (aerosoolvektor). Ettevõtte tootekandidaatide hulka kuuluvad 4D-125 X-linked retinitis pigmentosa (XLRP) raviks, 4D-110 choroideremia raviks, 4D-310 Fabry haiguse raviks, 4D-150 märja vanusega seotud makulaarse degeneratsiooni (märg AMD) raviks ja 4D-710 tsüstilise fibroosi kopsuhaiguse raviks.
| Industry: | Biotechnology & Medical Research (NEC) |
5858 Horton Street #455
Emeryville
EMERYVILLE
CALIFORNIA 94608
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 485,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com